Topical tacrolimus in the treatment of granuloma faciale

Cecchi, Roberto; Pavesi, Mario; Bartoli, Laura; Brunetti, Luigi

doi:10.1111/j.1365-4632.2009.04317.x

Cited by 8 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the mechanism of action of dapsone is not completely understood, it is thought to inhibit the activity of lysosomal enzymes, impede chemotaxis of neutrophils and eosinophils, and suppress inflammatory cytokines in the skin (62). The results of oral dapsone therapy vary (8,9,11,23,24,30,37,44,45,50,53,55,56,61). Common side-effects mentioned in the summary of product characteristics (SPC) include nausea and loss of appetite.…”

Section: Systemic Medicationsmentioning

confidence: 99%

Granuloma Faciale Treatment: A Systematic Review

Lindhaus¹,

Elsner²

2018

Acta Derm Venerol

View full text Add to dashboard Cite

Granuloma faciale is an uncommon benign chronic dermatosis characterized by reddish-brown to violaceous asymptomatic plaques appearing predominantly on the face. The pathogenesis of granuloma faciale remains unclear, and it is frequently unresponsive to therapy. This systematic review aims to summarize all recent publications on the management of granuloma faciale. The publications are mainly individual case reports, small case series and a few retrospective studies. Treatment options included topical, intralesional and systemic corticosteroids, topical pimecrolimus and tacrolimus, topical and systemic dapsone, systemic hydroxychloroquine, clofazimine, and tumour necrosis factor-alpha inhibitors. More invasive therapies using lasers as well as cryosurgery and surgery were also reported. Topical glucocorticosteroids and tacrolimus remain treatments of first choice, possibly supplemented by topical dapsone.

show abstract

Section: Systemic Medicationsmentioning

confidence: 99%

Granuloma Faciale Treatment: A Systematic Review

Lindhaus¹,

Elsner²

2018

Acta Derm Venerol

View full text Add to dashboard Cite

show abstract

“…More recent studies show good results with the use of topical tacrolimus and some types of laser, such as pulsed dye laser 595nm and KTP 532nm, directed to the prominent vascular component of pathology. 9 , 10 The lesions of the patient of the reported case disappeared after four months using topical tacrolimus 0.1%, progressing with mild residual hyperchromia and a few telangiectasias. She continues being periodically monitored, without recurrent lesions.…”

Section: Discussionmentioning

confidence: 80%

Granuloma faciale: a good therapeutic response with the use of topical tacrolimus

Lima

Maquiné

Silva

et al. 2015

An. Bras. Dermatol.

View full text Add to dashboard Cite

Granuloma faciale is a rare dermatosis of chronic course, benign, usually asymptomatic, first described in 1945 by Wingley. It is characterized by the appearance of well-defined, single or multiple papules, plaques and nodules, predominantly located in sun-exposed areas, especially the face. In this work we report the case of a female patient, 58 years old, evolving for ten years with multiple erythematous-brownish and asymptomatic papules on the face, whose histological examination confirmed the diagnosis of granuloma faciale. The patient was treated with topical tacrolimus, evolving with regression of lesions.

show abstract

“…Topical tacrolimus has recently been shown to be an effective treatment for GF [9, 10]. Tacrolimus contains an immunosuppressive agent that inhibits T cell proliferation and production of several proinflammatory cytokines, such as IL-2, IL-4, IL-5, IFN-γ and TNF-α [11].…”

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Granuloma Faciale with Topical Tacrolimus: A Case Report and Immunohistochemical Study

Tojo¹,

Fujimura²,

Kambayashi³

et al. 2012

Case Rep Dermatol

View full text Add to dashboard Cite

We report the case of a 55-year-old Japanese patient with granuloma faciale (GF) successfully treated with topical tacrolimus and describe the immunohistochemical study. Immunohistochemical staining revealed that the patient’s granuloma contained CD3⁺, CD4⁺, CD8⁺, CD68⁺ and CD163⁺ cells. Interestingly, these cells contained granulysin⁺ T cells and lacked Foxp3^high+ regulatory T cells. In addition, the macrophages were mainly CD163⁺, which suggested that the alternatively activated macrophage is one of the main components of GF. In summary, the present data shed light on the granuloma-composing cells and possible mechanisms in the treatment of GF with topical tacrolimus.

show abstract

Topical tacrolimus in the treatment of granuloma faciale

Cited by 8 publications

References 8 publications

Granuloma Faciale Treatment: A Systematic Review

Granuloma Faciale Treatment: A Systematic Review

Granuloma faciale: a good therapeutic response with the use of topical tacrolimus

Successful Treatment of Granuloma Faciale with Topical Tacrolimus: A Case Report and Immunohistochemical Study

Contact Info

Product

Resources

About